References
- CalderoneRAClancyCJCandida and Candidiasis2nd edWashington, DCAmerican Society of Microbiology2012
- ReesJRPinnerRWHajjehRABrandtMEReingoldALThe epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992–1993: results of population-based laboratory active surveillanceClin Infect Dis1998275113811479827260
- JarvisWREpidemiology of nosocomial fungal infections, with emphasis on Candida speciesClin Infect Dis1995206152615307548503
- HornDLNeofytosDAnaissieEJEpidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registryClin Infect Dis200948121695170319441981
- WilsonLSReyesCMStolpmanMSpeckmanJAllenKBeneyJThe direct cost and incidence of systemic fungal infectionsValue Health200251263411873380
- ZaoutisTEArgonJChuJBerlinJAWalshTJFeudtnerCThe epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysisClin Infect Dis20054191232123916206095
- PfallerMADiekemaDJEpidemiology of invasive candidiasis: a persistent public health problemClin Microbiol Rev200720113316317223626
- ClevelandAAHarrisonLHFarleyMMDeclining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008–2013: results from population-based surveillancePLoS One2015103e012045225822249
- SatohKMakimuraKHasumiYNishiyamaYUchidaKYamaguchiHCandida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospitalMicrobiol Immunol2009531414419161556
- KimMNShinJHSungHCandida haemulonii and closely related species at 5 university hospitals in Korea: identification, anti-fungal susceptibility, and clinical featuresClin Infect Dis2009486e57e6119193113
- ChowdharyAVossAMeisJFMultidrug-resistant Candida auris: ‘new kid on the block’ in hospital-associated infections?J Hosp Infect201694320921227634564
- MagoboRECorcoranCSeetharamSGovenderNPCandida auris-associated candidemia, South AfricaEmerg Infect Dis20142071250125124963796
- CalvoBMeloASPerozo-MenaAFirst report of Candida auris in America: clinical and microbiological aspects of 18 episodes of candidemiaJ Infect201673436937427452195
- BormanAMSzekelyAJohnsonEMComparative pathogenicity of United Kingdom isolates of the emerging pathogen Candida auris and other key pathogenic Candida speciesmSphere201614e001891627547827
- MizusawaMMillerHGreenRCan multidrug-resistant Candida auris be reliably identified in clinical microbiology laboratories?J Clin Microbiol201755263864027881617
- SchelenzSHagenFRhodesJLFirst hospital outbreak of the globally emerging Candida auris in a European hospitalAntimicrob Resist Infect Control201653527777756
- PfallerMADiekemaDJGibbsDLGlobal Antifungal Surveillance GroupResults from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusionJ Clin Microbiol20104841366137720164282
- HitchcockCACytochrome P-450-dependent 14 alpha-sterol demethylase of Candida albicans and its interaction with azole antifungalsBiochem Soc Trans19911937827871783216
- Joseph-HorneTHollomonDWMolecular mechanisms of azole resistance in fungiFEMS Microbiol Lett199714921411499141655
- HeimarkLShipkovaPGreeneJMechanism of azole antifungal activity as determined by liquid chromatographic/mass spectrometric monitoring of ergosterol biosynthesisJ Mass Spectrom200237326526911921367
- ClevelandAAFarleyMMHarrisonLHChanges in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008–2011Clin Infect Dis201255101352136122893576
- PfallerMARhombergPRMesserSAJonesRNCastanheiraMIsavuconazole, micafungin, and 8 comparator antifungal agents’ susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff valuesDiagn Microbiol Infect Dis201582430331325986029
- LockhartSREtienneKAVallabhaneniSSimultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analysesClin Infect Dis201764213414027988485
- MarichalPGorrensJCoeneMCLe JeuneLVanden BosscheHOrigin of differences in susceptibility of Candida krusei to azole antifungal agentsMycoses1995383–41111177477085
- PfallerMADiekemaDJGibbsDLGlobal Antifungal Surveillance GroupCandida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005J Clin Microbiol200846251552118077633
- MacPhersonSAkacheBWeberSDe DekenXRaymondMTurcotteBCandida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genesAntimicrob Agents Chemother20054951745175215855491
- HootSJSmithARBrownRPWhiteTCAn A643V amino acid substitution in Upc2p contributes to azole resistance in well-characterized clinical isolates of Candida albicansAntimicrob Agents Chemother201155294094221078937
- HeilmannCJSchneiderSBarkerKSRogersPDMorschhäuserJAn A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicansAntimicrob Agents Chemother201054135335919884367
- DunkelNLiuTTBarkerKSHomayouniRMorschhäuserJRogersPDA gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolateEukaryot Cell2008771180119018487346
- FlowersSABarkerKSBerkowELGain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicansEukaryot Cell201211101289129922923048
- SouzaACFuchsBBPinhatiHMCandida parapsilosis resistance to fluconazole: molecular mechanisms and in vivo impact in infected Galleria mellonella larvaeAntimicrob Agents Chemother201559106581658726259795
- BerkowELManigabaKParkerJEBarkerKSKellySLRogersPDMultidrug transporters and alterations in sterol biosynthesis contribute to azole antifungal resistance in Candida parapsilosisAntimicrob Agents Chemother201559105942595026169412
- JiangCDongDYuBMechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in ChinaJ Antimicrob Chemother201368477878523221625
- ReddingSWKirkpatrickWRSavilleSMultiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiationJ Clin Microbiol200341261962212574256
- vanden BosscheHMarichalPOddsFCLe JeuneLCoeneMCCharacterization of an azole-resistant Candida glabrata isolateAntimicrob Agents Chemother19923612260226101482129
- TavakoliMZainiFKordbachehMSafaraMRaoofianRHeidariMUpregulation of the ERG11 gene in Candida krusei by azolesDaru201018427628022615628
- WarrilowAGMartelCMParkerJEAzole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51)Antimicrob Agents Chemother201054104235424520625155
- SanglardDIscherFKoymansLBilleJAmino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agentsAntimicrob Agents Chemother19984222412539527767
- MorioFLogeCBesseBHennequinCLe PapePScreening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literatureDiagn Microbiol Infect Dis201066437338420226328
- MarichalPKoymansLWillemsensSContribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicansMicrobiology1999145Pt 102701271310537192
- LambDCKellyDEWhiteTCKellySLThe R467K amino acid substitution in Candida albicans sterol 14alpha-demethylase causes drug resistance through reduced affinityAntimicrob Agents Chemother2000441636710602724
- ChauASMendrickCASabatelliFJLoebenbergDMcNicholasPMApplication of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azolesAntimicrob Agents Chemother20044862124213115155210
- XiangMJLiuJYNiPHErg11 mutations associated with azole resistance in clinical isolates of Candida albicansFEMS Yeast Res201313438639323480635
- PereaSLópez-RibotJLKirkpatrickWRPrevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patientsAntimicrob Agents Chemother200145102676268411557454
- XuYChenLLiCSusceptibility of clinical isolates of Candida species to fluconazole and detection of Candida albicans ERG11 mutationsJ Antimicrob Chemother200861479880418218640
- GoldmanGHda Silva FerreiraMEdos Reis MarquesEEvaluation of fluconazole resistance mechanisms in Candida albicans clinical isolates from HIV-infected patients in BrazilDiagn Microbiol Infect Dis2004501253215380275
- FlowersSAColónBWhaleySGSchulerMARogersPDContribution of clinically derived mutations in ERG11 to azole resistance in Candida albicansAntimicrob Agents Chemother201559145046025385095
- KakeyaHMiyazakiYMiyazakiHNyswanerKGrimbergBBennettJEGenetic analysis of azole resistance in the Darlington strain of Candida albicansAntimicrob Agents Chemother200044112985299011036010
- GrossmanNTPhamCDClevelandAALockhartSRMolecular mechanisms of fluconazole resistance in Candida parapsilosis isolates from a U.S. surveillance systemAntimicrob Agents Chemother20155921030103725451046
- TanJZhangJChenWThe A395T mutation in ERG11 gene confers fluconazole resistance in Candida tropicalis causing candidemiaMycopathologia20151793–421321825398256
- EddouziJParkerJEVale-SilvaLAMolecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitalsAntimicrob Agents Chemother20135773182319323629718
- HullCMParkerJEBaderOFacultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin BAntimicrob Agents Chemother20125684223423222615281
- OrozcoASHigginbothamLMHitchcockCAMechanism of fluconazole resistance in Candida kruseiAntimicrob Agents Chemother19984210264526499756770
- FukuokaTJohnstonDAWinslowCAGenetic basis for differential activities of fluconazole and voriconazole against Candida kruseiAntimicrob Agents Chemother20034741213121912654649
- VenkateswarluKDenningDWKellySLInhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugsJ Med Vet Mycol199735119259061581
- SilvaDBRodriguesLMAlmeidaAAOliveiraKMGrisoliaABNovel point mutations in the ERG11 gene in clinical isolates of azole resistant Candida speciesMem Inst Oswaldo Cruz2016111319219926982177
- RicardoEMirandaIMFaria-RamosISilvaRMRodriguesAGPina-VazCIn vivo and in vitro acquisition of resistance to voriconazole by Candida kruseiAntimicrob Agents Chemother20145884604461124867987
- KellySLLambDCKellyDEResistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturationFEBS Lett1997400180829000517
- MartelCMParkerJEBaderOIdentification and characterization of four azole-resistant erg3 mutants of Candida albicansAntimicrob Agents Chemother201054114527453320733039
- MiyazakiTMiyazakiYIzumikawaKFluconazole treatment is effective against a Candida albicans erg3/erg3 mutant in vivo despite in vitro resistanceAntimicrob Agents Chemother200650258058616436713
- SanglardDIscherFParkinsonTFalconerDBilleJCandida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agentsAntimicrob Agents Chemother20034782404241212878497
- ChauASGurnaniMHawkinsonRLaverdiereMCacciapuotiAMcNicholasPMInactivation of sterol Delta5,6-desaturase attenuates virulence in Candida albicansAntimicrob Agents Chemother20054993646365116127034
- MiyazakiYGeberAMiyazakiHCloning, sequencing, expression and allelic sequence diversity of ERG3 (C-5 sterol desaturase gene) in Candida albicansGene19992361435110433965
- ReesDCJohnsonELewinsonOABC transporters: the power to changeNat Rev Mol Cell Biol200910321822719234479
- PrasadRGoffeauAYeast ATP-binding cassette transporters conferring multidrug resistanceAnnu Rev Microbiol201266396322703054
- TsaoSRahkhoodaeeFRaymondMRelative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistanceAntimicrob Agents Chemother20095341344135219223631
- MorschhäuserJMichelSStaibPSequential gene disruption in Candida albicans by FLP-mediated site-specific recombinationMol Microbiol199932354755610320577
- SanglardDIscherFMonodMBilleJSusceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitorsAntimicrob Agents Chemother19964010230023058891134
- SchilligRMorschhäuserJAnalysis of a fungus-specific transcription factor family, the Candida albicans zinc cluster proteins, by artificial activationMol Microbiol20138951003101723844834
- CosteATCrittinJBauserCRohdeBSanglardDFunctional analysis of cis- and trans-acting elements of the Candida albicans CDR2 promoter with a novel promoter reporter systemEukaryot Cell2009881250126719561319
- SiikalaERautemaaRRichardsonMSaxenHBowyerPSanglardDPersistent Candida albicans colonization and molecular mechanisms of azole resistance in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patientsJ Antimicrob Chemother201065122505251320876623
- CaudleKEBarkerKSWiederholdNPXuLHomayouniRRogersPDGenomewide expression profile analysis of the Candida glabrata Pdr1 regulonEukaryot Cell201110337338321193550
- KatiyarSKEdlindTDIdentification and expression of multidrug resistance-related ABC transporter genes in Candida kruseiMed Mycol200139110911611270397
- SanglardDIscherFCalabreseDMajcherczykPABilleJThe ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agentsAntimicrob Agents Chemother199943112753276510543759
- TorelliRPosteraroBFerrariSThe ATP-binding cassette transporter-encoding gene CgSNQ2 is contributing to the CgPDR1-dependent azole resistance of Candida glabrataMol Microbiol200868118620118312269
- LampingERanchodANakamuraKAbc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida kruseiAntimicrob Agents Chemother200953235436919015352
- BarchiesiFCalabreseDSanglardDExperimental induction of fluconazole resistance in Candida tropicalis ATCC 750Antimicrob Agents Chemother20004461578158410817712
- VandeputtePLarcherGBergèsTRenierGChabasseDBoucharaJPMechanisms of azole resistance in a clinical isolate of Candida tropicalisAntimicrob Agents Chemother200549114608461516251302
- PaoSSPaulsenITSaierMHJrMajor facilitator superfamilyMicrobiol Mol Biol Rev19986211349529885
- GaurMPuriNManoharlalRMFS transportome of the human pathogenic yeast Candida albicansBMC Genomics2008957919055746
- WirschingSMichelSMorschhäuserJTargeted gene disruption in Candida albicans wild-type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolatesMol Microbiol200036485686510844673
- MorschhäuserJBarkerKSLiuTTBlaB-WarmuthJHomayouniRRogersPDThe transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicansPLoS Pathog2007311e16417983269
- DunkelNBlassJRogersPDMorschhäuserJMutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strainsMol Microbiol200869482784018577180
- CostaCRibeiroJMirandaIMClotrimazole drug resistance in Candida glabrata clinical isolates correlates with increased expression of the drug:H(+) antiporters CgAqr1, CgTpo1_1, CgTpo3, and CgQdr2Front Microbiol2016752627148215
- ChenXMageeBBDawsonDMageePTKumamotoCAChromosome 1 trisomy compromises the virulence of Candida albicansMol Microbiol200451255156514756793
- RustchenkoEChromosome instability in Candida albicansFEMS Yeast Res20077121117311580
- SelmeckiAForcheABermanJAneuploidy and isochromosome formation in drug-resistant Candida albicansScience2006313578536737016857942
- CosteASelmeckiAForcheAGenotypic evolution of azole resistance mechanisms in sequential Candida albicans isolatesEukaryot Cell20076101889190417693596
- SeervaiRNJonesSKJrHirakawaMPPormanAMBennettRJParasexuality and ploidy change in Candida tropicalisEukaryot Cell201312121629164024123269
- HarrisonBDHashemiJBibiMA tetraploid intermediate precedes aneuploid formation in yeasts exposed to fluconazolePLoS Biol2014123e100181524642609
- PolákováSBlumeCZárateJAFormation of new chromosomes as a virulence mechanism in yeast Candida glabrataProc Natl Acad Sci U S A200910682688269319204294
- MarichalPVanden BosscheHOddsFCMolecular biological characterization of an azole-resistant Candida glabrata isolateAntimicrob Agents Chemother19974110222922379333053
- AlarcoAMRaymondMThe bZip transcription factor Cap1p is involved in multidrug resistance and oxidative stress response in Candida albicansJ Bacteriol199918137007089922230
- SchubertSBarkerKSZnaidiSRegulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicansAntimicrob Agents Chemother20115552212222321402859
- TalibiDRaymondMIsolation of a putative Candida albicans transcriptional regulator involved in pleiotropic drug resistance by functional complementation of a pdr1 pdr3 mutation in Saccharomyces cerevisiaeJ Bacteriol199918112312409864335
- SanglardDIscherFMarchettiOEntenzaJBilleJCalcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulenceMol Microbiol200348495997612753189
- CruzMCGoldsteinALBlankenshipJRCalcineurin is essential for survival during membrane stress in Candida albicansEMBO J200221454655911847103
- MansfieldBEOlteanHNOliverBGAzole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungiPLoS Pathog201069e100112620941354
- FranzRKellySLLambDCKellyDERuhnkeMMorschhäuserJMultiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strainsAntimicrob Agents Chemother19984212306530729835492
- WhiteTCPfallerMARinaldiMGSmithJReddingSWStable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patientOral Dis19973Suppl 1S102S1099456667
- MartínezMLópez-RibotJLKirkpatrickWRHeterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosisJ Antimicrob Chemother200249351552411864952
- FerrariSIscherFCalabreseDGain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulencePLoS Pathog20095e100026819148266
- SasseCDunkelNSchäferTThe stepwise acquisition of fluconazole resistance mutations causes a gradual loss of fitness in Candida albicansMol Microbiol201286353955622924823
- MacCallumDMCosteAIscherFJacobsenMDOddsFCSanglardDGenetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infectionAntimicrob Agents Chemother20105441476148320086148
- CalvetHMYeamanMRFillerSGReversible fluconazole resistance in Candida albicans: a potential in vitro modelAntimicrob Agents Chemother19974135355399055988
- HuangMMcClellanMBermanJKaoKCEvolutionary dynamics of Candida albicans during in vitro evolutionEukaryot Cell201110111413142121890821
- CowenLEPredicting the emergence of resistance to antifungal drugsFEMS Microbiol Lett200120411711682169
- AndersonJBEvolution of antifungal-drug resistance: mechanisms and pathogen fitnessNat Rev Microbiol20053754755615953931